A living WHO guideline on drugs for covid-19

submited by
Style Pass
2021-09-26 17:00:11

Disclaimer: This infographic is not a validated clinical decision aid. This information is provided without any representations, conditions or warranties that it is accurate or up to date. BMJ and its licensors assume no responsibility for any aspect of treatment administered with the aid of this information. Any reliance placed on this information is strictly at the user's own risk. For the full disclaimer wording see BMJ's terms and conditions: https://www.bmj.com/company/legal-information/

New recommendation Pre-prints of four randomised trials (from a larger adaptive randomised master protocol) among patients with non-severe illness, and the RECOVERY trial among severe and critically ill patients, triggered this guideline update. This resulted in a conditional recommendation to use a combination of casirivimab and imdevimab in non-severe patients for those at highest risk of severe disease. The RECOVERY trial included a crucial subgroup analysis demonstrating differential benefits (effect modification) associated with serological status. The Guideline Development Group (GDG) made a second conditional recommendation to use casirivmab-imdevimab in patients with severe and critical infection, if the individual has seronegative status.

Prior recommendations (a) A strong recommendation for interleukin-6 receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19; (b) a recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (c) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (d) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (e) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (f) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (g) a conditional recommendation against remdesivir in hospitalised patients with covid-19.

Leave a Comment